Humacyte (NASDAQ:HUMA) Given Buy Rating at HC Wainwright

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $15.00 target price on the stock, up from their prior target price of $12.00. HC Wainwright’s target price points to a potential upside of 333.53% from the company’s current price.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price target on shares of Humacyte in a research report on Friday, September 20th. BTIG Research reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a report on Monday, September 9th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research note on Thursday, November 21st. Finally, TD Cowen restated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $13.43.

Humacyte Trading Down 2.3 %

HUMA stock opened at $3.46 on Friday. The business has a fifty day moving average of $4.85 and a 200-day moving average of $5.87. The company has a market cap of $435.47 million, a P/E ratio of -2.58 and a beta of 1.38. Humacyte has a twelve month low of $2.48 and a twelve month high of $9.97. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

Insider Buying and Selling

In related news, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the sale, the chief executive officer now directly owns 1,730,884 shares in the company, valued at $7,615,889.60. This represents a 13.12 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 1,500,000 shares of company stock valued at $6,606,799. 11.20% of the stock is owned by corporate insiders.

Institutional Trading of Humacyte

Hedge funds and other institutional investors have recently made changes to their positions in the business. Endowment Wealth Management Inc. grew its position in Humacyte by 3.1% in the second quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock valued at $482,000 after purchasing an additional 3,000 shares in the last quarter. nVerses Capital LLC bought a new position in shares of Humacyte in the 2nd quarter valued at about $28,000. Private Advisor Group LLC increased its position in shares of Humacyte by 1.8% in the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after acquiring an additional 6,510 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Humacyte by 32.5% during the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after purchasing an additional 8,557 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Humacyte by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock worth $125,000 after purchasing an additional 8,965 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.